Starting Multiple Sclerosis Treatment Right Away Versus Later

This trial is testing whether starting Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) right away—even before leaving the clinic or hospital—helps people with relapsing multiple sclerosis have fewer disease flare-ups over 18 months compared to starting the medication later in outpatient care. The medication is given as a subcutaneous injection (a shot under the skin). Researchers will track relapses, disability changes, brain imaging, and immune cell changes in the blood.

Currently, people with relapsing multiple sclerosis often wait to start treatment, but researchers wonder if starting this immune-suppressing treatment immediately after a relapse or hospitalization might prevent more flare-ups and slow disease progression better than waiting.